Aerus ActivePure Technology Air Purifier Kills COVID-19 on Surfaces in Lab Results
Aerus is awaiting final approval from the FDA for Emergency Use Authorization for the Aerus Hydroxyl Blaster with ActivePure Technology. The use of this product is for reducing Covid-19 surface pathogens. The results have also been submitted by Aerus to the FDA-equivalent Canadian and European Union regulators. Therefore, Aerus are requesting that they clear Aerus ActivePure devices to combat reducing Covid-19. Aerus expects to receive clearances in all jurisdictions.
Additionally, Aerus is also running independent laboratory tests to demonstrate the efficacy of ActivePure Technology on airborne SARS-CoV-2 virus for FDA clearance.
Controlled, independent laboratory studies have established the efficacy of ActivePure Technology in Aerus products including:
- 93% surface kill in three hours of live SARS-CoV-2. Even when covered by a protective biofilm, with the Aerus Hydroxyl Blaster with ActivePure Technology
- 98% surface kill in six hours of live SARS-CoV-2, even when covered by a protective biofilm, with the Aerus Hydroxyl Blaster with ActivePure Technology
- 99.999% kill rate of airborne RNA viruses in just 30 minutes with the Aerus Medical Guardian with ActivePure Technology, an FDA 510(k) Cleared Class II Medical Device
- 99.9999% kill rate of airborne RNA viruses in 60 minutes with the Aerus Medical Guardian with ActivePure Technology